Forty (40) hospitalized patients with a severe form of COVID-19 accompanied by complications of acute respiratory distress syndrome (ARDS) will be enrolled in the study.
The main endpoint that will measure the effectiveness of the study is the number of days spent without a ventilator during the entire 28 days of the study. Monitoring the survival rate and the level of safety will be made at 60 th day and the 26 and 52 weeks.
'We are excited to expand our COVID-19 program to additional territory and look forward to starting the clinical trial of our PLX cells for the treatment of severe cases of COVID-19 and having developed complications of ARDS in
In addition to this study in
PLX cells against COVID-19
PLX cells can be administered without a prescription and, once marketed, can be made in large quantities. Pluristem believes that its PLX cells will provide a key advantage in the fight against the global COVID-19 pandemic. PLX cells are similar to allogeneic mesenchymal cells; the immunomodulatory properties of these cells trigger the natural regulators of the immune system - M2 macrophages and T cells, and thus can prevent or reverse dangerous overactivation of the immune system. Therefore, PLX cells can potentially reduce the incidence and / or severity of pneumonia caused by COVID-19, hopefully leading to a better prognosis for patients.Results from previous preclinical studies with PLX cells have shown therapeutic benefits in animal studies for pulmonary hypertension, pulmonary fibrosis, acute kidney injury and gastrointestinal injury, which are potential complications of serious infections. to COVID-19. Clinical data on the use of PLX cells have demonstrated their great immunomodulatory power in patients who have undergone major surgery. Preliminary clinical data, obtained at the end of a 28-day follow-up in patients with COVID-19 in the intensive care unit and treated under a compassionate use program, have been previously published. The potential capacities of PLX cells,combined with the safety profile seen in clinical trials involving hundreds of patients around the world, place PLX cells as a potential treatment to mitigate the damaging effects of COVID-19 on tissue.
About
This notice contains forward-looking information within the meaning of the US Securities Act and the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995.
Contact:
Tel: 972-74-7107194
Email: danar@pluristem.com
(C) 2020 Electronic News Publishing, source